Peer-reviewed veterinary case report
Survival factors in dogs with multiple skin mast cell tumors
By O'Connell, K & Thomson, M·Published in Veterinary and comparative oncology·2013·The Springwood Centre, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases.
- Species:
- dog
Plain-English summary
A group of 63 dogs with multiple skin tumors called mast cell tumors (MCTs) was studied to understand how different factors affect their health outcomes. The research found that dogs with a grade 3 MCT had a much shorter survival time compared to those with lower-grade tumors. Additionally, dogs treated with certain chemotherapy drugs (vinblastine and lomustine) faced a significantly higher risk of dying. The study highlighted that dogs with a single MCT located on a leg had better survival rates. Overall, the prognosis varied widely among the dogs based on their specific conditions and treatments.
People also search for: dog skin tumors treatment · mast cell tumor prognosis in dogs · grade 3 mast cell tumor survival rate
Abstract
Sixty-three dogs with multiple contemporaneous cutaneous mast cell tumours (MCTs) were identified. The aim of this study was to determine the significance of breed, concurrent dermatological condition; number of cutaneous MCTs, size, location, histological grade and mitotic index; completeness of excision (complete, close or incomplete); local recurrence, metastasis and adjuvant therapy for the prognostic evaluation of dogs with a unique disease presentation of multiple, simultaneously occurring cutaneous MCTs. On the basis of multivariable survival analysis, dogs with one recorded grade 3 MCT had shorter progression-free survival (PFS) times (18.7 versus 2.2 months) and median survival times (MSTs) (24 versus 3 months). Dogs treated with adjuvant vinblastine/lomustine had a 16 times increased risk of dying. MSTs were found to be significantly longer in dogs with one recorded MCT on an extremity. For all dogs, the PFS (range 14-1835 days) and MSTs (range 28-1835 days) were not reached.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22235766/